Colorado Blood Cancer Institute

Recent papers from Colorado Blood Cancer Institute

1. Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple SclerosisNeurology Neuroimmunology & Neuroinflammation · 2026
2. Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trialNature Medicine · 2026
3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology · 2018
4. Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphomaJournal for ImmunoTherapy of Cancer · 2026
5. Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALLBlood Advances · 2026
6. Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaBlood · 2026
7. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaBlood · 2026
8. Optec/Optal: A phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Journal of Clinical Oncology · 2026
9. First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.Journal of Clinical Oncology · 2026
10. Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.Journal of Clinical Oncology · 2026
11. Sickle cell disease-associated pulmonary hypertension: an integrated framework linking pathologies, mechanisms, and clinical phenotypesEBioMedicine · 2026
12. P40 | Efficacy and Safety of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: Updated Phase 2 Results From the Redirectt-1 Study With Extended Follow-UpSHILAP Revista de lepidopterología · 2026
13. P33 | Arlocabtagene Autoleucel, a Gprc5d-Targeted Car T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior RegimensSHILAP Revista de lepidopterología · 2026
14. Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM studyNature Communications · 2026
15. Abstract 5193: Novel SynKIR-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B-cell non-Hodgkin lymphoma xenograft mice and shows early clinical signalCancer Research · 2026
16. Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myelomaBlood Advances · 2026
17. Revised Recommendations for Restarting Teclistamab Following Dose Delays: Insights from the MajesTEC-1 Study on Clinical Safety, and from Simulated Pharmacokinetics and Cytokine DynamicsTargeted Oncology · 2026
18. Safety and Efficacy of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-cell Therapy, in relapsed/refractory Multiple Myeloma: Preliminary Results from the DURGA-1 phase 1b/2 StudyTransplantation and Cellular Therapy · 2026
19. Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)Transplantation and Cellular Therapy · 2026
20. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Assessment in Adults with Motor, Sensory, and Language Barriers, Following Chimeric Antigen Receptor (CAR) T cell Therapy in the Outpatient SettingTransplantation and Cellular Therapy · 2026